Fourth Quarter 2019 Earnings CallMarch 12, 2020

© 2020 Amyris, Inc. All rights reserved.

Cautionary Notes

2

FORWARD-LOOKING STATEMENTS

This presentation and oral statements accompanying this presentation contain forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as expected revenue, including product and royalty revenues, EBITDA, gross profit and operating expenses in 2019 and beyond, including related growth rates, anticipated growth for Amyris’s Biossance business, expected production volume, delivery and cost reduction in 2019 and 2020, and expectations regarding Amyris’s financial and operational results and ability to achieve its business plan in 2019 and beyond. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris’s liquidity and ability to fund operating and capital expenses, risks related to potential delays or failures in development, production and commercialization of products, risks related to Amyris's reliance on third parties, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise.

Note: Figures for fourth quarter 2019 are preliminary and unaudited.

NON-GAAP FINANCIAL INFORMATION

This presentation and oral statements accompanying this presentation contain both GAAP and non-GAAP financial information. Amyris considers non-GAAP financial information to be a helpful measure to assess its operational performance and for financial and operational decision-making. Where non-GAAP financial measures are presented in these slides or in oral statementsaccompanying this presentation, a presentation of the most directly comparable GAAP financial measure and a quantitative reconciliation between the non-GAAP financial measure and the most directly comparable GAAP financial measure may be found in the slides of this presentation or in the news release distributed today, which is available at investors.amyris.com.

© 2020 Amyris, Inc. All rights reserved. 3

Q4 2019 Actuals

$18.5M $10.7M$11.4M$40.5M

Q4 2018 Actuals

$12.1M$0.1M$4.2M

$16.4M

RevenueProduct Revenue Licenses & RoyaltiesCollaborations & GrantsTotal

Non- GAAP % Gross Profit55.4% 24.5%

Adjusted EBITDA (i)(i) Excludes depreciation & amortization and stock compensation expense

Financial Highlights (unaudited)

-$40.8M -$27.5M

© 2020 Amyris, Inc. All rights reserved. 4

2019 Actuals

$59.9M $54.0M$38.6M

$152.6M

2018 Actuals

$33.6M$7.7M

$22.3M$63.6M

RevenueProduct Revenue Licenses & RoyaltiesCollaborations & GrantsTotal

Non- GAAP % Gross Profit56.0% 56.9%

Adjusted EBITDA (i,ii)(i) Excludes depreciation & amortization and stock compensation expense

Financial Highlights (unaudited)

-$118.6M -$104.8M

Business Model Creates Value for Partners & Customers

New Formulations

Platform Ingredients

Disruptive Product Efficacy

Leading Brands

New Stories

PROVEN TECH PLATFORM

DELIVERING TO THE MARKET

Sell Ingredients to the Leading Brands Launch Consumer Health & Beauty Brands

OwningConsumerMindshare

VALUE CREATION MODELIngredients:• Farnesene• Patchouli • Squalane • Sclareol• Manool • Bisabolol• Fragrance 5*• Flavor 1* • Reb M

*Confidential molecules© 2020 Amyris, Inc. All rights reserved. 5

15 26 40 6297

127 154194

222 237 250299

2017-Q1 2017-Q2 2017-Q3 2017-Q4 2018-Q1 2018-Q2 2018-Q3 2018-Q4 2019-Q1 2019-Q2 2019-Q3 2019-Q4

Biossance is on Track to Become a Billion Dollar Brand

6© 2020 Amyris, Inc. All rights reserved.

2017-2019 CAGR = ~350%

TOTAL # OF BIOSSANCE.COM CUSTOMERS (000’s)

Biossance Key Growth Drivers

SALES

Dec 2018 = 104%

June 2019 = 141%

Dec 2019 = 135%

Jan 2020 = 205%2019 YE: in all 495 Sephora NA stores

2020: will participate in Sephora NA’s 100 new store openings

Sephora End Caps produces 2-2.5X more retail revenue Sephora Monthly Productivity*

*Sephora Productivity is how Biossance performs compares to its peers in revenue per square foot

113 130240

297 296 255

2017 2018 2019 YEEC (17 SKUs) Wall (6SKUs)

DOORS

© 2020 Amyris, Inc. All rights reserved.

65

-

20

40

60

80

100

120

140

160

2019 Actual 2020 Projection

Full Year

7

Product & Royalty Revenue Trend

(i) Excludes Vitamin E Revenues

(i)

$M

2X plus

$M2016-2019 CAGR:Clean Beauty: 83%

Health & Ingredients: 36%

Potential Range

© 2020 Amyris, Inc. All rights reserved. 8

Q4 2019 Results (Unaudited)

($ in M) Q4 2019 Q4 2018

Revenue

Renewable products $ 18.5 $ 12.1

Licenses and royalties $ 10.7 $ 0.1

Grants and collaborations $ 11.4 $ 4.2

Total Revenue $ 40.5 $ 16.4

Non-GAAP gross profit (a)$ 22.5 $ 4.0 Q4 2019 GM 55.4%

GAAP Operating expenses $ 49.7 $ 48.8 Change 2%

Non-GAAP Operating expenses (b)$ 45.4 $ 40.9 Change 11%

GAAP net income (loss) attributable to common shareholders $ (77.4) $ (48.6) Change 59%

Non-GAAP net income (loss) attributable to common shareholders (c)$ (45.0) $ (56.6) Change -20%

(a) excludes depreciation and amortization, lower of cost or net realizable value adjustments, and excess capacity.

(b) excludes stock based compensation expense and depreciation and amortization.

(c) excludes stock based compensation, gain/loss on change in fair value of derivatives, gain/loss on extinguishment of debt, and cumulative dividends on preferred stock.

SUMMARY FINANCIAL INFORMATION

© 2020 Amyris, Inc. All rights reserved. 9

FY 2019 Results (Unaudited)

($ in M) FY 2019 FY 2018

Revenue

Renewable products $ 59.9 $ 33.6

Licenses and royalties $ 54.0 $ 7.7

Grants and collaborations $ 38.6 $ 22.3

Total Revenue $ 152.6 $ 63.6

Non-GAAP gross profit (a)$ 85.5 $ 36.1 FY 2019 GM 56.0%

GAAP Operating expenses $ 198.3 $ 163.5 Change 21%

Non-GAAP Operating expenses (b)$ 181.7 $ 145.9 Change 25%

GAAP net income (loss) attributable to common shareholders $ (270.4) $ (223.1) Change 21%

Non-GAAP net income (loss) attributable to common shareholders (c)$ (169.2) $ (171.0) Change -1%

(a) excludes depreciation and amortization, lower of cost or net realizable value adjustments, and excess capacity.

(b) excludes stock based compensation expense and depreciation and amortization.

(c) excludes stock based compensation, gain/loss on change in fair value of derivatives, gain/loss on extinguishment of debt, and cumulative dividends on preferred stock.

SUMMARY FINANCIAL INFORMATION

© 2020 Amyris, Inc. All rights reserved.

Debt Schedule

10

Amyris, Inc. Summary of Debt

Holder Security Maturity Rate Cash/SharesAs of

12/31/19 ($ M)

Q1'20 Conversions & Principle Reductions

($ M)

As of 3/12/20

($ M)

* Foris Secured Various 12.5% Cash 96.4 41.0 55.4

Convertible notes due 2022 Unsecured Sep-22 5.0% Cash/Shares 66.0 17.7 48.3

* DSM loan Unsecured Dec-21 10.0% Cash 25.0 - 25.0

* Naxyris Secured Jul-22 12.75% Cash 24.4 - 24.4

Schottenfeld Secured Various 12.0% Cash 20.4 - 20.4

Nikko notes Secured Various Various Cash 13.4 0.5 12.9

Ginkgo note Unsecured Oct-22 12.0% Cash 12.0 - 12.0

* Total Unsecured Mar-20 12.0% Cash 10.2 1.1 9.1

* DSM loan 2 Secured Aug-22 12.5% Cash 8.0 - 8.0

Nikko Aprinnova note B Unsecured Aug-20 2.75% Cash 0.9 - 0.9

* Foris Unsecured Jan-23 12.0% Cash 19.0 19.0 -

Other loans Unsecured Various Various Cash 1.8 - 1.8

Total Debt $297.5 $79.3 $218.2

Unamortized debt discount (35.7) (13.7) (22.0)

Total Debt (net of debt discount) $261.8 $65.6 $196.2

* Insiders * Insiders' principal $183.0 $121.9

Recent Production Results – Q4 2019

• Produced 10 products in Q4 for total product volume of 1,578 tons which is anew quarterly record. Introduced our 10th product

• Process improvements – Clean Beauty examples

• Squalane production record during Q2 2019 at 300 tons and another record at 400 tons for Q4

• Squalane production of 1,345 tons for 2019 was up 68% over 2018 volume

• Transferred Hemisqualane production to lower cost location and improved re-processed waste to reduce manufacturing unit cost by 25%

• Total 2019 product volume of 3,700 tons (up 90% over 2018 product volume)

• Production volume growth up 250% from 2017

© 2020 Amyris, Inc. All rights reserved. 11

Cost of Goods Sold & Production Improvements

• Improved unit costs every quarter – gross product margin increased from 3% to 36%

• Optimized production footprint - 95% of production now deployed at low cost locations relative to 70% in Q1 2019

• Delivered Process improvements – for example reduced unit costs by ~30% for Hemisqualane, HP Fene and RebM

• Prepared plan to deliver 4,200 tons in 2020

• Secured the production capacity we need for 2020 at low cost facilities.

© 2020 Amyris, Inc. All rights reserved. 12

© 2020 Amyris, Inc. All rights reserved. 13

2020 Expectations

1

2

3

4

Revenue of $220 million or better – have $20-$40 million of upside not included due to focus on removing uncertainty

Gross margin of between 60-70%

Clean Beauty gross sales of around $130 million

Expect to commercialize 2-3 new molecules

© 2020 Amyris, Inc. All rights reserved.